Allergan Plc (AGN)
$193.02 0.00 (0.00%)
18:30 EDT AGN Stock Quote Delayed 30 Minutes
Previous Close $193.02
Market Cap 75.75B
PE Ratio -37.63
Volume (Avg. Vol.)
Day's Range 193.02 - 193.02
52-Week Range 114.27 - 202.21
Dividend & Yield 2.88 (1.49%)
AGN Stock Predictions, Articles, and Allergan Plc News
- From InvestorPlace
- From the Web
Wall Street analysts see significant upside in these 10 stocks to buy. And all ten have other reasons for optimism as well.
Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?
Realty Income, Allergan, Boeing, Mylan and the S&P 500 were big movers on Tuesday. You have to see these must-see stock charts.
Allergen needs to win back investors as the company continues to look for new drug products. AGN stock is stuck in a narrow trading range.
Not all stocks are lifted by a rising tide, especially these blue-chip stocks that look like they're in for some trouble.
AMZN, TAP, ALGN and AGN are just some of the stocks on the rise as we head into the second quarter of the year.
As Goldman Sachs moves away from the strong balance sheet investing strategy, here are 6 new stocks to buy.
Biotech stocks offer more than just capital gains; some of them pay dividends. Here are three dividend-paying biotechs to consider.
Don't ignore Dow Jones stocks. They can still power your portfolio. Here are 5 of the best to own in 2019 and beyond!
Pharmaceutical stocks have been on the rebound and many are raising their prices this year. What does that mean for business?
AGN stock is taking a beating today on some bad news about Allergan's breast implants and concerns over links to cancer.
Biotech stocks can still pay you some big yields. Here are five of the best dividend stocks in the pharma sector.
Biogen stock reaffirmed its dominance in MS and the neurosciences market. At a low P/E mutliple, investors should look at BIIB again.
Drug stocks have been beaten up ever since the 2015 collapse of Valeant, but many of them are now too cheap to ignore.
The short-term outlook on AGN stock is messy due to drug pricing issues. But the long-term outlook remains promising - thanks to the company's wide moat and stable growth prospects.
Gene-Therapy Treatments for Tay-Sachs, Sickle Cell, Other Diseases to Be Featured in Online Gathering
From Simply Wall St
Even when a business is losing money, it’s possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/heres-why-were-watching-beam-therapeuticss-nasdaqbeam-cash-burn-situation/">Read More...</a></div>